RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Beats Estimates By $0.02 EPS

Key Points

• RenovoRx beat earnings estimates: The company reported a quarterly loss of $0.05 per share, $0.02 better than consensus, while revenue climbed 61% sequentially and 115% year over year to $909,000. Management raised 2026 revenue guidance to $3.75 million–$4.25 million.
• Commercial expansion is accelerating: Active cancer centers grew from 16 to 21, with 42 more in the pipeline and a year-end target of at least 36. Management expects repeat orders and conversions related to the TIGeR-PaC trial to support another record quarter.
• Clinical progress continues, but losses remain significant: The TIGeR-PaC Phase III trial has reported 78 of 86 required events, with topline data expected in the second half of 2027. RenovoRx posted a $3.4 million operating loss and had $9.5 million in cash at quarter-end, leaving potential need for additional capital.

RenovoRx (NASDAQ:RNXT - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02, FiscalAI reports. RenovoRx had a negative return on equity of 135.03% and a negative net margin of 823.98%.

Here are the key takeaways from RenovoRx's conference call:

• Record revenue and upgraded guidance: Second-quarter revenue rose 61% sequentially and 115% year over year to $909,000, prompting RenovoRx to raise 2026 revenue guidance to $3.75 million–$4.25 million from $3 million–$4 million.
• Commercial expansion is accelerating: Active commercial cancer centers increased from 16 to 21 during the quarter, with 42 additional centers in the pipeline and a target of at least 36 active centers by year-end. Management said repeat orders and site conversions from the TIGeR-PaC trial should support another record revenue quarter in Q3.
• Clinical and product opportunity expanded: RenovoCath was used commercially for the first time in a sarcoma patient, providing physician-driven evidence of potential applications beyond locally advanced pancreatic cancer. Management also cited supportive clinical publications and growing physician advocacy.
• Phase III trial enrollment completed: The TIGeR-PaC study is nearly fully randomized, with 78 of the required 86 events reported as of August 11, 2026. Trial completion is expected in the first half of 2027, with initial topline data anticipated in the second half of 2027.
• Company remains loss-making and cash-constrained: RenovoRx reported a $3.4 million operating loss and held $9.5 million in cash at quarter-end. Although management expects cash to fund operations into the second half of 2027 and projects cash-flow break-even in Q4 2027, further capital could be needed if growth or trial timelines fall short.

RenovoRx Stock Down 2.6%

NASDAQ:RNXT traded down $0.03 during mid-day trading on Wednesday, hitting $1.12. 458,398 shares of the stock traded hands, compared to its average volume of 309,943. The stock has a market capitalization of $50.46 million, a price-to-earnings ratio of -3.39 and a beta of 0.99. RenovoRx has a 52 week low of $0.70 and a 52 week high of $1.45. The firm's 50 day moving average is $0.93 and its two-hundred day moving average is $0.93.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on RNXT shares. Weiss Ratings raised RenovoRx from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, July 17th. Wall Street Zen raised RenovoRx from a "strong sell" rating to a "sell" rating in a research report on Saturday, July 18th. Finally, Ascendiant Capital Markets increased their price target on RenovoRx from $13.50 to $14.00 and gave the company a "buy" rating in a report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Bleichroeder LP lifted its stake in shares of RenovoRx by 11.4% during the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company's stock worth $504,000 after acquiring an additional 61,379 shares during the last quarter. Wealthspire Advisors LLC bought a new stake in shares of RenovoRx during the fourth quarter worth $212,000. Citadel Advisors LLC purchased a new stake in shares of RenovoRx during the third quarter valued at $154,000. Geode Capital Management LLC grew its holdings in shares of RenovoRx by 9.9% in the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company's stock worth $467,000 after purchasing an additional 31,730 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in RenovoRx in the 2nd quarter worth about $98,000. Institutional investors own 3.10% of the company's stock.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company's lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source